We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 02, 2021

Canagliflozin and Major Cardiovascular and Kidney Events in Patients With Different Baseline Levels of HbA1c, Disease Duration, and Treatment Intensity



Additional Info

Disclosure statements are available on the authors' profiles:

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program
Diabetologia 2021 Nov 01;64(11)2402-2414, TK Young, JW Li, A Kang, HJL Heerspink, C Hockham, C Arnott, BL Neuen, S Zoungas, KW Mahaffey, V Perkovic, D de Zeeuw, G Fulcher, B Neal, M Jardine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading